Share on LinkedInShare on LinkedIn

ARTICLE · 24 MAY 2023

Amgen V. Sanofi – Impermissible Functional Claiming?

On April 28 the Supreme Court heard oral arguments on Amgen's petition of the Federal Circuit's decision affirming the district court's decision on JMOL that Amgen's antibody claims...

United StatesIntellectual Property

On April 28 the Supreme Court heard oral arguments on Amgen's petition of the Federal Circuit's decision affirming the district court's decision on JMOL that Amgen's antibody claims lacked an enabling disclosure. Much of the argument revolved around what was the quantum of experimentation that was too much for a claim to be enabled. At the end of Sanofi's argument its counsel cited the Morse case where the Supreme Court invalidated Morse claim 8 which defined the transmission of symbols in solely functional terms:

"Eighth. I do not propose to limit myself to the specific machinery or parts of machinery described in the foregoing specification and claims; the essence of my invention being the use of the motive power of the electric or galvanic current, which I call electro-magnetism, however developed for marking or printing intelligible characters, signs, or letters, at any distances, being a new application of that power of which I claim to be the first inventor

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from